Metabolic dysfunction-associated steatotic liver disease (MASLD) may differ biologically from obesity-linked MASH, a mouse study suggests, with salt driving liver inflammation without obesity.
|Articles|January 24, 2014
Why you need to test your edge server ASAP
Test your system to manage the three main risks in the complex process
Advertisement
Edge servers are the secure systems that plans must use in the exchanges to transmit
And there are risk implications for issuers within the complex edge-server program:
- Financial Risk: The amount of reinsurance and risk adjustment payments that an Issuer will receive will be completely dependent upon the accuracy and completion of file submissions. Errors in this process will cause significant financial risk and cash flow issues.
- Compliance Risk: Given that Federal funds are at stake, inaccurate submissions create a significant compliance risk for Issuers.
- Operational Workload Risk: Inaccurate data submissions will generate high volumes of error records that will need to be investigated, corrected and resubmitted.
Source: HealthScape Advisors
Advertisement
Related to this article
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.
Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.
States have to turn that information into medical frailty determinations that are clinically credible, consistent, and workable across large Medicaid populations.
A meta-analysis found steatotic liver disease in 75% of patients with sleep-disordered breathing and that CPAP lowered liver enzymes but not liver fat.
Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard researchers find no evidence of that happening so far.
State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread pricing bans, and compliance risks.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Final GLOBE drug model projects much smaller savings while 2027 Part D premiums split
2
FAQ: State PBM reform in 2026—What's new since spring
3
New lean MASH mouse model could guide more targeted liver disease treatment in humans
4
Billing for lab tests, especially genetic tests, is a mess. Bill Kerr has ideas about how to clean it up.
5